Market Size of Pneumonia Testing Industry
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 1.97 Billion |
| Market Size (2029) | USD 2.75 Billion |
| CAGR (2024 - 2029) | 6.93 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Pneumonia Testing Market Analysis
The Pneumonia Testing Market size is estimated at USD 1.97 billion in 2024, and is expected to reach USD 2.75 billion by 2029, growing at a CAGR of 6.93% during the forecast period (2024-2029).
Pneumonia testing market is growing at good rate as pneumonia is a life-threatening disease wherein testing helps the people to know in advance and further, they can be cured quickly. The major factor attributing to the growth of the market are rise in adoption of POC testing and development in the field of nucleic acid detection. Moreover, the awareness level is increasing day by day which results in early diagnosis, hence promoting the growth of pneumonia testing market.
In addition, pneumonia is found to be the major cause of death in children. For instance, in 2018 according to UNICEF, about 800000 children died due to pneumonia. Also, these diseases are more prevalent in South Asia and African countries. However, due to the limited detection capability and accuracy, the market is expected to be hampered to a certain extent.
Pneumonia Testing Industry Segmentation
Pneumonia is a lung disease caused by bacteria, virus and fungi infections in which inflammation in the air sacs, or alveoli is occurred. Pneumonia Testing is segmented By Product Type, Method Type, Technology Type, End User and Geography.
| By Product Type | |
| Consumable | |
| Analyzer |
| By Method Type | |
| Immunodiagnostic | |
| Molecular Diagnostic | |
| Point-of-Care (POC) Testing |
| By Technology | |
| Enzyme-Linked Immunosorbent Assay (ELISA) | |
| Immunofluroscence | |
| Immunohistochemistry (IHC) | |
| Polymerase Chain Reaction (PCR) | |
| Others |
| By End-user | |
| Hospitals | |
| Diagnostic Centers | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Pneumonia Testing Market Size Summary
The pneumonia testing market is experiencing significant growth, driven by the increasing adoption of point-of-care (POC) testing and advancements in nucleic acid detection technologies. This growth is largely attributed to the critical nature of pneumonia as a life-threatening disease, where early testing and diagnosis can lead to timely treatment and improved patient outcomes. The rising awareness about pneumonia and its early diagnosis is further propelling the market. POC testing, known for its efficiency and rapid results, is becoming the preferred method for pneumonia detection, especially in regions with high prevalence of the disease, such as South Asia and Africa. Despite its benefits, the market faces challenges due to limited detection capabilities and accuracy, which could hinder its growth to some extent.
Regionally, North America is anticipated to hold a significant share of the global pneumonia testing market, primarily due to its aging population and increased awareness of pneumonia as a leading cause of mortality. The region benefits from a well-established healthcare infrastructure, rising healthcare expenditure, and frequent product approvals and launches, such as BioMérieux's FDA clearance for its respiratory panel. The market is characterized by fragmentation and competitiveness, with major players like Abbott, Bio-Rad Laboratories, bioMerieux SA, and Thermo Fisher Scientific leading the market. These companies are instrumental in driving the market forward through their innovative products and solutions, catering to the growing demand for effective pneumonia testing.
Pneumonia Testing Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rise in Popularity of POC Testing
-
1.2.2 Surge in Awareness Towards Early Diagnosis
-
1.2.3 Increase in Government Expenditure on Healthcare
-
-
1.3 Market Restraints
-
1.3.1 Limited Detection Capability and Accuracy
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Product Type
-
2.1.1 Consumable
-
2.1.2 Analyzer
-
-
2.2 By Method Type
-
2.2.1 Immunodiagnostic
-
2.2.2 Molecular Diagnostic
-
2.2.3 Point-of-Care (POC) Testing
-
-
2.3 By Technology
-
2.3.1 Enzyme-Linked Immunosorbent Assay (ELISA)
-
2.3.2 Immunofluroscence
-
2.3.3 Immunohistochemistry (IHC)
-
2.3.4 Polymerase Chain Reaction (PCR)
-
2.3.5 Others
-
-
2.4 By End-user
-
2.4.1 Hospitals
-
2.4.2 Diagnostic Centers
-
2.4.3 Others
-
-
2.5 Geography
-
2.5.1 North America
-
2.5.1.1 United States
-
2.5.1.2 Canada
-
2.5.1.3 Mexico
-
-
2.5.2 Europe
-
2.5.2.1 Germany
-
2.5.2.2 United Kingdom
-
2.5.2.3 France
-
2.5.2.4 Italy
-
2.5.2.5 Spain
-
2.5.2.6 Rest of Europe
-
-
2.5.3 Asia-Pacific
-
2.5.3.1 China
-
2.5.3.2 Japan
-
2.5.3.3 India
-
2.5.3.4 Australia
-
2.5.3.5 South Korea
-
2.5.3.6 Rest of Asia-Pacific
-
-
2.5.4 Middle-East and Africa
-
2.5.4.1 GCC
-
2.5.4.2 South Africa
-
2.5.4.3 Rest of Middle-East and Africa
-
-
2.5.5 South America
-
2.5.5.1 Brazil
-
2.5.5.2 Argentina
-
2.5.5.3 Rest of South America
-
-
-
Pneumonia Testing Market Size FAQs
How big is the Pneumonia Testing Market?
The Pneumonia Testing Market size is expected to reach USD 1.97 billion in 2024 and grow at a CAGR of 6.93% to reach USD 2.75 billion by 2029.
What is the current Pneumonia Testing Market size?
In 2024, the Pneumonia Testing Market size is expected to reach USD 1.97 billion.
